SpringWorks Therapeutics Inc expected to post a loss of $1.24 a share - Earnings Preview

SpringWorks Therapeutics

23/02/2024 14:12

* SpringWorks Therapeutics Inc  SWTX.OQ   SWTX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
February 26 (estimated) for the period ending December 31 2023
    * The Stamford Connecticut-based  company is expected to
report
revenue of $600 thousand, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for SpringWorks Therapeutics
Inc
is for a loss of $1.24 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for SpringWorks
Therapeutics Inc is $60.00​, above​ its last closing price
of $49.11. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.29       -1.33      -1.27     Beat    4.5
 Jun. 30 2023  -1.25       -1.26      -1.25     Beat    1
 Mar. 31 2023  -1.31       -1.25      -1.18     Beat    5.9​
 Dec. 31 2022  -1.22       -1.22      -1.17     Beat    4.2
 ​​Sep.        -1.30       -1.32      -1.37     Missed  -3.8
 30 2022                                                
 Jun. 30 2022  -1.22       -1.20      -1.41     Missed  -17.2​
 Mar. 31 2022  -1.07       -1.02      -1.26     Missed  -23.1
 Dec. 31 2021  -0.88       -0.88      -1.15     Missed  -31
 This summary was machine generated February 23 at 14:12 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)